Efficacy of oral tacrolimus on intestinal Behcet's disease

Inflammatory Bowel Diseases

Volumn 16, Issue 2, 2010, Pages 188-189

  Matsumura, Kayoko ^a   Nakase, Hiroshi ^a   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN A; MESALAZINE; PREDNISOLONE; TACROLIMUS;

ADULT; BEHCET DISEASE; CASE REPORT; COLON ULCER; COLONOSCOPY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; BEHCET SYNDROME; COLITIS, ULCERATIVE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 73949147972     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20970     Document Type: Letter

References (8)

1. Baba S, Maruta M, Ando K, et al. Intestinal Behçet's disease: report of five cases. Dis Colon Rectum. 1976;19:428-440.
2. Hassard PV, Binder SW, Nelson V, et al. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology. 2001;120:995-999.
3. Sakane T, Mochizuki M, Inaba G, et al. A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions. Ryumachi. 1995;35:802-813.
4. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999;106:723-728.
5. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. J Gastroenterol. 2007;42:737-745.
6. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol. 1989;143:718-726.
7. McMaster P, Mirza DF, Ismail T, et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit. 1995;17:602-605.
8. Ogata H, Matsui T, Nakamura M, et al. A randomized dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255-1262.